Yes , check point inhibitors are becoming popular for a reason , they allow our immune system to recognize and fight cancers , unfortunately they also can produce those terrible side effects when our immune system start to fight our healthy organs , to the point that treatment could be fatal,
Also in about 3-6 months patients becoming resistant to this treatment .
-as per Dr Patterson.

Look that both of this problems can be avoided when Leronlimab will be add together to treatment .
So even if treating cancer not CCR5 positive , but when medicine like Keytruda or Optdivo is use , most probably with time , Leronlimab will be added just to prevent side effects and resistance to treatment .

There are 2 studies now ongoing with Keytruda and CCR5 inhibitors ,
one phase 1 with Pfizer in Germany , and one phase 2 with Merck in USA.
When results will be much better than Keytruda without CCR5 inhibitors , this treatment may start to become more of routine treatments,

And so far Leronlimab is the best of all CCR5 inhibitors , and the only one without one serious side effects ..


Imo as always .